Medtronic bows to the inevitable
Paying $1.1bn for Heartware five years ago was not the company’s smartest move.
The US FDA gets tough
Tecentriq follows Opdivo, Imfinzi and Keytruda in having a US approved use knocked out.
Despite Imfinzi, US accelerated approvals surge
More and more drugs are being approved conditionally on flimsy data, and Imfinzi is just the second to be pulled after failing a confirmatory trial.
Boston deadheads its Lotus
Beset with problems from the off, the Lotus Edge aortic valve has finally been discontinued.
The FDA gets aggressive with Covid-19 antibody tests
Chembio’s antibody test is the first to have its authorisation revoked. It might not be the last.
